Today we are excited to invite you to join our Online Linkedin Webinar that will be taking place on February 16^th (JST) from 10:30 AM.

 

In this webinar series we have being looking at examples of both clinical NASH trials as well as non-clinical study designs. For the 4^th installment in this series, we would also like to examine the roll that a PEGylated fibroblast growth factor 21 analogue can play in the treatment of NASH.

 

As you may already know, preclinical models that have a high clinical correlation are extremely important when it comes to successfully developing effective NASH treatments. That is why we highly recommend that you join our free webinar!

 

Click here to participate ► webinar

 

At SMC, we have successfully conducted countless drug efficacy studies and are one of the leading experts in the field of NASH.

 

Please feel free to contact us if you have any questions about SMC, including if you would like more information on this webinar or our experience as a CRO.

 

■Webinar title：Creating high quality non-clinical study designs based on clinical trials (#Series 4: FGF21)

■Webinar Link

■Date： February 16^th (Thu) 10:30 - 11:00 AM (JST)

■Agenda

・Introduction of NASH clinical trials

・Introduction of non-clinical NASH study design (#4: FGF21).

・Introduction of mouse model that develops liver cancer from NASH.

・Achievements with STAM™ model

 

■STAM™ model

The STAM™ model was developed here at SMC Laboratories and is the world's first pathological mouse model to show the progression of NASH to liver cancer.

This model shows a similar pathology to human NASH (steatosis → NASH → liver fibrosis → HCC).